A positron-emission tomography study to determine brain exposure of [11C]savolitinib in healthy volunteers

Study identifier:D5084C00016

ClinicalTrials.gov identifier:NCT06348355

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Open-label, Positron-Emission Tomography Study to Determine Brain Exposure of [11C]savolitinib in Healthy Volunteers

Medical condition

Healthy Volunteers

Phase

Phase 1

Healthy volunteers

Yes

Study drug

[11C]savolitinib, Savolitinib

Sex

All

Actual Enrollment

7

Study type

Interventional

Age

50 Years - 65 Years

Date

Study Start Date: 12 Apr 2024
Primary Completion Date: 24 Jun 2024
Study Completion Date: 24 Jun 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Other

Verification:

Verified 01 Jul 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria